Effectiveness of anti-resorption therapies of postmenopausal osteoporosis
Authors:
J. Štěpán
Authors‘ workplace:
III. interní klinika 1. lékařské fakulty UK a VFN Praha, přednosta prof. MUDr. Štěpán Svačina, DrSc., MBA
Published in:
Vnitř Lék 2007; 53(3): 293-299
Category:
Review
Overview
The aim of this article is to justify a need for evaluation of the absolute risk of fractures, to compare efficacy of antiresorptive therapies as indicated by large clinical trials, and to review currently available methods to assess efficacy of therapies in individual patients. It is emphasized that adherence to therapies is influenced not only by the individual bone efficacy and safety of the drug but also by beneficial impacts of the treatment on tissues other than bone.
Key words:
osteoporosis – fracture – BMD – biochemical markers – treatment
Sources
1. NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785–795.
2. Kado DM, Duong T, Stone KL et al. Incident vertebral fractures and mortality in older women: a prospective study. Osteoporos Int 2003; 14: 589–594.
3. Štěpán J, Payer J, Abrahámová J. Stratifikace léčby postmenopauzální osteoporózy. Prakt Lék 2004; 84: 500–506.
4. Lufkin EG, Whitaker MD, Nickelsen T et al. Treatment of established postmenopausal osteoporosis with raloxifenea randomized trial. J Bone Miner Res 1998; 13: 1747–1754.
5. Maricic M, Adachi JD, Sarkar S et al. Early effects of raloxifene on clinical vertebral fractures at 12 months in postme-nopausal women with osteoporosis. Arch Intern Med 2002; 162: 1140–1143.
6. Pols HA, Felsenberg D, Hanley DA et al. Multinational, placebocontrolled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Osteoporos Int 1999; 9: 461–468.
7. Reginster J, Minne HW, Sorensen OH et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11: 83–91.
8. Cranney A, Guyatt G, Griffith L et al. Meta-analyses of therapies for postme-nopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002; 23: 570–578.
9. Kado DM, Browner WS, Palermo L et al. Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group. Arch Intern Med 1999; 159: 1215–1220.
10. Lindsay R, Silverman SL, Cooper C et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001; 285: 320–323.
11. Štěpán J, Šmíd M, Prokeš M et al. Ekonomicke aspekty osteoporozy. Čas Lék Česko 1998; 137: 707–715.
12. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 1535–1541.
13. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JA-MA 1998; 280: 2077–2082.
14. McClung MR, Geusens P, Miller PD et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001; 344: 333–340.
15. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JA-MA 1999; 282: 1344–1352.
16. Štěpán JJ: Algoritmus diagnostiky a léčby osteoporózy. Farmakoterapie 2005; 1: 485–494.
17. Cummings SR, Palermo L, Browner W et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. JA-MA 2000; 283: 1318–1321.
18. Štěpán JJ, Zikán V. Calcitonin load test to assess the efficacy of salmon calcitonin. Clin Chim Acta 2003; 336: 49–55.
19. Hochberg MC, Ross PD, Black D et al. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Arthritis Rheum 1999; 42: 1246–1254.
20. Štěpán J. Kvalita kosti: které účinky léčby můžeme monitorovat a co to před-pokládá? Osteologicky Bull 2003; 8: 75–81.
21. Garnero P. Markers of bone turnover for the prediction of fracture risk. Osteo-poros Int 2000; 11: 55–65.
22. Gerdhem P, Ivaska KK, Alatalo SL et al. Biochemical markers of bone metabo-lism and prediction of fracture in elderly women. J Bone Miner Res 2004; 19: 386–393.
23. Borah B, Dufresne TE, Chmielewski PA et al. Risedronate preserves bone ar-chitecture in postmenopausal women with osteoporosis as measured by three-di-mensional microcomputed tomography. Bone 2004; 34: 736–746.
24. Delmas PD, Genant HK, Crans GG et al. Severity of prevalent vertebral fractu-res and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003; 33: 522–532.
25. Roy DK, Pye SR, Lunt M et al. Falls explain between center differences in the incidence of limb fracture across Europe. Bone 2002; 31: 712–717.
26. Dukas L, Schacht E, Stahelin HB. In elderly men and women treated for osteoporosis a low creatinine clearance of <65 ml/min is a risk factor for falls and fractures. Osteoporos Int 2005; 16: 1683–1690.
27. Cramer JA, Amonkar MM, Hebborn A et al. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteopo-rosis. Curr Med Res Opin 2005; 21: 1453–1460.
28. Turbi C, Herrero Beaumont G et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clincal practice: An openlabel, prospective, nonrandomized, observational study. Clin Ther 2004; 26: 245–256.
29. Martino S, Cauley JA, Barrett Connor E et al. Continuing outcomes relevant to Evista: breast cancer incidence in post-menopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 2004; 96: 1751–1761.
30. Richer E, Lewis MA, Odvina CV et al. Reduction in normalized bone elasticity following long–term bisphosphonate treatment as measured by ultrasound cri-tical angle reflectometry. Osteoporos Int 2005; 16: 1384–1392.
31. Odvina CV, Zerwekh JE, Rao DS et al. Severely suppressed bone turnover: a po-tential complication of alendronate the-rapy. J Clin Endocrinol Metab 2005; 90: 1294–1301.
32. Štěpán JJ, Burr DB, Pavo I et al. Pre-valent fractures, low bone mineral densi-ty and ageing are associated with greater histomorphometric indicators of microdamage accumulation in postmenopau-sal women. J Bone Miner Res 2005; 20: S90–91.
33. Caro JJ, Ishak KJ, Huybrechts KF et al. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003–1008.
34. Bone HG, Hosking D, Devogelaer JP et al. Ten years’ experience with alendro-nate for osteoporosis in postmenopausal women. N Engl J Med 2004; 350: 1189–1199.
35. Tremollieres FA, Pouilles JM, Ribot C. Withdrawal of hormone replacement therapy is associated with significant ver-tebral bone loss in postmenopausal women. Osteoporos Int 2001; 12: 385–390.
36. Michalská D, Štěpán JJ, Basson BR et al. The effect of raloxifene after disconti-nuation of long-term alendronate treat-ment of postmenopausal osteoporosis. J Clin Endocrinol Metab 2006; 91: 870–877.
37. Silva MJ, Gibson LJ. Modeling the mechanical behavior of vertebral trabecular bone: effects of agerelated changes in microstructure. Bone 1997; 21: 191–199.
38. Ettinger B, San Martin J, Crans GG et al. Response of markers of bone turnover and bone density to teriparatide in postmenopausal women previously trea-ted with an antiresorptive drug. J Bone Mineral Research 2003; 18: S15.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2007 Issue 3
Most read in this issue
- Systemic and paraneoplastic manifestations of malignant diseases
- Hashimoto’s encepahlopthy – a rare and unusual syndrome
- Acute humoral rejection of renal transplant
- Detection of ectopic gastric mucosa in Meckel’s diverticulum by means of scintigraphy with 99mTc-pertechnetate in a 24-year old man